Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | CENPE | Q02224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197628 | 0.85 | CSNK2A1 (0.72) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL6215544 | 0.84 | CSNK2A1 (1.00) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL12768177 | 0.84 | CSNK2A1 (0.70) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL3718847 | 0.84 | CSNK2A1 (0.70) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL3722004 | 0.84 | CSNK2A1 (0.70) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL2359346 | 0.82 | RORC (0.53) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL10088644 | 0.81 | CSNK2A1 (0.49) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL4331816 | 0.81 | CSNK2A1 (0.49) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL25144732 | 0.81 | CSNK2A1 (0.66) | CSNK2A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL3940203 | 0.81 | CSNK2A1 (0.66) | CSNK2A1MEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-4221919-A | Antiinflammatory substituted phenylacetic acids | SPOFA, UNITED PHARMACEUTICAL WORKS (CS) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | CSNK2A1 2025/4885MEN1 1528/4885KMT2A 2928/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | CSNK2A1 1930/4885MEN1 2001/4885KMT2A 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.